David Rusnak

David has over twenty years of experience in government and industry at the National Institute of Environmental Health Sciences (NIEHS) and GlaxoSmithKline.  He has experience in cell-based and immunoassays, specializing in assay development and automation.  While at GlaxoSmithKline, David’s cell-based assays were instrumental in the discovery and development of the approved cancer therapy, Tykerb.  The cell-based system he developed for rapid analysis of drug combinations has resulted in three patents and FDA filings for expanded indications for Tykerb.  While in the Metabolic Biomarker Lab at GSK, David evaluated and validated immunoassays for measuring circulating markers of metabolic disease progression.

At BioAgilytix, David has served as a Bioanalytical Project Manager for immuno- and cell-based assay development and has coordinated computer system validation. He has co-authored 29 peer-reviewed publications, been an inventor of four patents, and presented in professional scientific symposia. David received a B.S. in Biological Sciences and a B.S. in Biochemistry from North Carolina State University.